A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
This important study is looking into a new medicine called ALKS 2680 for adults who have Narcolepsy Type 1. Narcolepsy Type 1 is a condition that makes people feel very sleepy during the day and can cause sudden muscle weakness (cataplexy). The main goal is to find out if ALKS 2680 helps people feel less sleepy, using a special questionnaire called the Epworth Sleepiness Scale. Researchers will also check how safe the medicine is. To do this, some participants will receive the new medicine, while others will receive a 'dummy' medicine (placebo) that looks the same but contains no active drug. This helps scientists compare the effects fairly.
En un coup d'œil
De quoi parle cette étude ?
This study is focused on a medical condition called Narcolepsy Type 1. People with Narcolepsy Type 1 often struggle with extreme tiredness during the day, which can make it hard to concentrate or stay awake. They might also experience 'cataplexy,' which is a sudden loss of muscle control often triggered by strong emotions like laughter or surprise. This can be very disruptive to daily life.
The research team is testing a new medicine called ALKS 2680. The main purpose of the study is to see if this new medicine can help people with Narcolepsy Type 1 feel less sleepy during the day. They will measure changes in sleepiness using a widely recognised questionnaire called the Epworth Sleepiness Scale over 12 weeks. They will also be very careful to check for any side effects and make sure the medicine is safe.
The study is designed as a 'double-blind, placebo-controlled' trial. This means that neither you nor your study doctor will know whether you are receiving the new medicine (ALKS 2680) or a 'placebo' (a dummy pill with no active drug). This is a standard and important way to ensure the results are accurate and unbiased, so we can truly understand if the new medicine is working.
Points clés
- This study is testing a new medicine (ALKS 2680) for Narcolepsy Type 1.
- It aims to see if the medicine reduces daytime sleepiness and is safe.
- Participants will receive either the new medicine or a placebo (dummy pill).
- Neither you nor your doctor will know which you are receiving.
- The study lasts for 12 weeks of treatment, with regular clinic visits.
- It's for adults aged 18 and above with Narcolepsy Type 1.
Qui peut être éligible ?
This study is for adults aged 18 and over. Both men and women can take part.
To be considered for this study, you must have a confirmed diagnosis of Narcolepsy Type 1.
There will be other, more detailed criteria that the study doctors will discuss with you. These are in place to make sure the study includes people who are most likely to benefit from or safely participate in the trial, and to ensure the results of the study are clear and reliable.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have a diagnosis of Narcolepsy Type 1?
- Êtes-vous en mesure d'assister à des rendez-vous réguliers à la clinique ?
- Are you willing to take study medication as directed?
- Are you comfortable with the possibility of receiving a placebo instead of the active medicine?
En quoi consiste la participation ?
If you decide to take part in this study, you would visit the study clinic regularly over a period of 12 weeks. At these visits, you would have check-ups with the study doctor or nurse, answer questionnaires about your sleepiness and other symptoms, and you might have some special sleep tests. You would also take the study medicine or placebo as instructed. Throughout the study, the team will closely monitor your health and any side effects you might experience. After the 12 weeks of treatment, there will likely be follow-up appointments to check on you.
Risques et avantages potentiels
Emplacements (5)
- —Non vérifiéItalie
- —Non vérifiéFrance
- —Non vérifiéPays-Bas
- —Non vérifiéEspagne
- —Non vérifiéBelgique
Questions fréquentes
What is Narcolepsy Type 1?
Narcolepsy Type 1 is a long-term brain condition that causes overwhelming daytime sleepiness and can lead to sudden muscle weakness called cataplexy, often triggered by strong emotions.
What is ALKS 2680?
ALKS 2680 is a new medicine being tested to see if it can help reduce sleepiness in adults with Narcolepsy Type 1.
Que signifie 'contrôlé par placebo' ?
It means some people will get the new medicine, and others will get a 'dummy' pill (placebo) that looks the same but has no active drug. This helps us see if the new medicine truly works.
Saurai-je si je reçois le vrai médicament ou le placebo ?
No, neither you nor your study doctor will know what you are receiving. This is called 'double-blind' and helps ensure the study results are fair.
Combien de temps l'étude durera-t-elle pour moi ?
The main part of the study involves taking the medicine for 12 weeks, with regular visits and follow-ups before and after this period.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.